钆塞酸二钠增强MRI诊断肝细胞癌:移行期和肝胆期廓清的价值
这项回顾性研究纳入178例患者的203个经手术证实的肝结节(186个肝细胞癌、17个非肝细胞癌),比较廓清分别限于门静脉期、扩展至移行期、扩展至肝胆期三种钆塞酸二钠增强MRI标准的诊断效能。廓清扩展至肝胆期的敏感度95.2%(177/186)高于扩展至移行期的90.9%(169/186,P=0.01)和限于门静脉期的75.3%(140/186,P<0.01);扩展至移行期与肝胆期的特异度均为82%(14/17),与限于门静脉期的94.1%(16/17)相似(P=0.47)。
要点
- 排除典型血管瘤和靶环样结节后,可将廓清观察扩展至移行期或肝胆期。
- 廓清扩展至肝胆期敏感度95.2%,高于限于门静脉期的75.3%。
- 扩展廓清至移行期或肝胆期后特异度82%,与限于门静脉期94.1%相似。
核心结论
- 排除典型血管瘤和靶环样表现结节后,将廓清表现扩展至移行期或肝胆期而非仅限门静脉期,可在不降低特异度的情况下提高诊断肝细胞癌的敏感度。
研究设计与样本
- 回顾性研究,纳入2012年1月至12月超声监测发现肝结节并接受钆塞酸二钠增强MRI的患者178例(平均年龄55.3岁±9.1),共203个经手术证实的肝结节(186个肝细胞癌、17个非肝细胞癌),直径均≤3.0 cm。
关键影像表现/征象
- 以动脉期高强化伴廓清为诊断依据,廓清分别限于门静脉期、扩展至移行期或扩展至肝胆期构成三种MRI诊断标准。
- 结节若呈明显T2高信号或靶环样表现,则排除肝细胞癌诊断。
诊断标准与关键数值
- 廓清扩展至肝胆期的敏感度为95.2%(177/186),高于扩展至移行期的90.9%(169/186,P=0.01)和限于门静脉期的75.3%(140/186,P<0.01)。
- 廓清扩展至移行期与扩展至肝胆期的特异度均为82%(14/17),与限于门静脉期的94.1%(16/17)相似(P=0.47)。
临床应用与阅片要点
- 阅片时除门静脉期外,可同时观察移行期和肝胆期的廓清表现以提高肝细胞癌检出敏感度。
- 诊断肝细胞癌前需先排除典型血管瘤及呈靶环样表现的结节。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Current Liver Imaging Reporting and Data System guidelines define the washout appearance of gadoxetic acid-enhanced MRI only during the portal venous phase. Defining washout only during the portal venous phase may lead to lower sensitivity for diagnosis of hepatocellular carcinoma (HCC). Purpose To compare the diagnostic performances of three gadoxetic acid-enhanced MRI criteria for HCC according to the phases during which washout appearance was determined. Materials and Methods In this retrospective study, patients with a hepatic nodule detected at US surveillance for HCC from January to December 2012 underwent gadoxetic acid-enhanced MRI. Three diagnostic MRI criteria for HCC were defined according to the phases during which washout appearance was observed, with the presence of arterial phase hyperenhancement and hypointensity noted (a) only during the portal venous phase, with washout confined to the portal venous phase; (b) during the portal venous phase or transitional phase, with washout extended to the transitional phase; or (c) during the portal venous, transitional, or hepatobiliary phase, with washout extended to the hepatobiliary phase. If a nodule showed marked T2 hyperintensity or a targetoid appearance, it was precluded from the diagnosis of HCC. The sensitivity and specificity were compared by using a generalized estimating equation. Results A total of 178 patients were included (mean age ± standard deviation, 55.3 years ± 9.1) with 203 surgically confirmed hepatic nodules (186 HCCs and 17 non-HCCs) measuring 3.0 cm or smaller. The sensitivity with washout extended to the hepatobiliary phase (95.2% [177 of 186]) was better than that with washout extended to the transitional phase (90.9% [169 of 186]; P = .01) and washout confined to the portal venous phase (75.3% [140 of 186]; P < .01). The specificity with extensions of washout to the transitional phase and hepatobiliary phase (82% [14 of 17] for both) was similar to that obtained with washout confined to the portal venous phase (94.1% [16 of 17]) (P = .47). Conclusion After exclusion of typical hemangiomas and nodules with a targetoid appearance, extending washout appearance to the transitional or hepatobiliary phase (instead of restricting it to the portal venous phase) allowed higher sensitivity without a reduction in specificity. © RSNA, 2019 See also the editorial by Fowler and Sirlin in this issue.
引用
- Kim DH, Choi SH, Kim SY, et al. Gadoxetic Acid-enhanced MRI of Hepatocellular Carcinoma: Value of Washout in Transitional and Hepatobiliary Phases. Radiology. 2019. PMID: 30990381. doi:10.1148/radiol.2019182587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。